SAN DIEGO, Feb. 13, 2017 /PRNewswire/ -- Mirati
Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D, Ph.D., President and CEO
of Mirati, will provide a corporate overview during a fireside chat
presentation at the Leerink Partners 6th Annual Global
Healthcare Conference on Thursday, March 16,
2017 at 11:30 a.m. ET (8:30am
PT) in New York City.
An audio webcast of the presentation will be accessible on the
"Investors" page of Mirati's corporate website
at www.mirati.com. A replay of the presentation will be
available at the same location for 60 days following the
conference.
About Mirati Therapeutics
Mirati Therapeutics, Inc.
is a clinical-stage biopharmaceutical company focused on developing
a pipeline of targeted oncology products intended to treat specific
genetic and epigenetic drivers of cancer in selected subsets of
cancer patients with unmet needs. Our clinical pipeline consists of
three product candidates: glesatinib, sitravatinib and
mocetinostat. Both glesatinib and sitravatinib are orally
bioavailable, spectrum-selective kinase inhibitors with distinct
target profiles that are in development for the treatment of
patients with NSCLC and other solid tumors. Glesatinib targets the
MET receptor tyrosine kinase family and is in Phase 2
clinical development. Sitravatinib targets RET
rearrangements, CHR4q12 amplifications (encompassing
KDR, PDGFRA and KIT), and CBL and
AXL mutations, and is in Phase 1b clinical development.
Sitravatinib is also being evaluated in combination with nivolumab,
a PD-1 inhibitor, for the treatment of patients with NSCLC.
Sitravatinib is a potent inhibitor of the TAM (Tyro, Axl,
Mer) and split (KDR, KIT) tyrosine kinase families,
which regulate multiple stages in the cancer immunity cycle and are
thought to enhance anti-tumor immunity by improving the efficacy of
immune checkpoint inhibitors (anti PD-1/PD-L1).
Our third product candidate is mocetinostat, an orally
bioavailable, spectrum-selective Class 1 histone deacetylase
inhibitor. Mocetinostat is in Phase 1b/2 clinical development in
combination with durvalumab, MedImmune's anti-PD-L1 immune
checkpoint inhibitor, for the treatment of patients with
NSCLC. More information is available at www.mirati.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mirati-therapeutics-to-present-at-leerink-partners-6th-annual-global-healthcare-conference-300406381.html
SOURCE Mirati Therapeutics, Inc.